

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
PATRICK *et al.*
Appl. No.: 10/591,962
(*U.S. Natl. Phase of PCT/GB2005/000907*)
Intl. Appl. Filed: March 9, 2005
For: **Boronate Medicaments Suitable for Short
Duration Anticoagulation**

Confirmation No.: 6858
Art Unit: *To Be Assigned*
Examiner: *To Be Assigned*
Atty. Docket: 2451.0130000/BJD/GER

**Information Disclosure Statement
Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on this Information Disclosure Statement are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents **FP1-FP31** and **NPL1-NPL72** are submitted herewith. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patent documents **US1** to **US42**, cited on the attached IDS Form, PTO/SB/08A, are not submitted.

Document **FP16**, WO 98/31688 A1, is in a foreign language. Based on the English language abstract, this document appears to relate to boronic acid derivatives that are said to inhibit angiogenesis.

In accordance with the recent Federal Circuit decision in *Dayco Prods., Inc. v. Total Containment, Inc.*, 329 F.3d 1358 (Fed. Cir. 2003), Applicants submit herewith Office Actions from:

co-pending U.S. Patent Application No. 10/937,181, listed as document **NPL63**;

co-pending U.S. Patent Application No. 10/659,178, listed as documents **NPL64** and **NPL65**;

co-pending U.S. Patent Application No. 10/658,971, listed as documents **NPL66-NPL68**;

co-pending U.S. Patent Application No. 11/077,620, listed as documents **NPL69** and **NPL70**;

co-pending U.S. Patent Application No. 11/078,097, listed as document **NPL71**;
and

co-pending U.S. Patent Application No. 10/937,854, listed as document **NPL72**.

The Examiner's attention is directed to the following co-pending U.S. patent applications:

Application No. 10/658,971, inventors Madge, A., *et al.*, filed September 9, 2003, which published as US 2004/0138175 A1, listed as document **US34**;

Application No. 10/937,181, inventors Walter, A., *et al.*, filed September 8, 2004, which published as US 2005/0119226 A1, listed as document **US35**;

Application No. 10/937,854, inventors Madge, A., *et al.*, filed September 8, 2004, which published as US 2005/0176651 A1, listed as document **US36**;

Application No. 11/078,097, inventors Combe-Marzelle, S.M., *et al.*, filed March 9, 2005, which published as US 2005/0282757 A1, listed as document **US37**;

Application No. 10/659,178, inventors Madge, D.J., *et al.*, filed September 9, 2003, which published as US 2005/0288253 A1, listed as document **US38**;

Application No. 11/077,620, inventor Boucher, O.V.A., filed March 9, 2005, which published as US 2006/0084592 A1, listed as document **US39**;

Application No. 11/438,823, inventors Deadman, J.J. *et al.*, which published as US 2006/0229257, listed as document **US42**;

Application No. 11/980,398, inventors Madge, D.J. *et al.*, which has not published; and

Application No. 10/592,265, inventors Combe-Marzelle *et al.*, which has not published, and which is the U.S. national phase of international application no. PCT/GB2005/000908, filed March 9, 2005, which published as WO 2005/084686 A2, listed as document **FP31**.

The identification of these U.S. Patent Applications is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Grant E. Reed
Attorney for Applicants
Registration No. 41,264

Date: January 16, 2008

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

740544v1